Search

Your search keyword '"Schaefer, Miriam"' showing total 94 results
Start Over Author "Schaefer, Miriam"
94 results on '"Schaefer, Miriam"'

1. Machine learning based prediction and the influence of complement – Coagulation pathway proteins on clinical outcome: Results from the NEURAPRO trial

Author

Susai, Subash Raj, Mongan, David, Healy, Colm, Cannon, Mary, Cagney, Gerard, Wynne, Kieran, Byrne, Jonah F., Markulev, Connie, Schäfer, Miriam R., Berger, Maximus, Mossaheb, Nilufar, Schlögelhofer, Monika, Smesny, Stefan, Hickie, Ian B., Berger, Gregor E., Chen, Eric Y.H., de Haan, Lieuwe, Nieman, Dorien H., Nordentoft, Merete, Riecher-Rössler, Anita, Verma, Swapna, Street, Rebekah, Thompson, Andrew, Ruth Yung, Alison, Nelson, Barnaby, McGorry, Patrick D., Föcking, Melanie, Paul Amminger, G., and Cotter, David

Published
2022
Full Text
View/download PDF

2. The association of plasma inflammatory markers with omega-3 fatty acids and their mediating role in psychotic symptoms and functioning: An analysis of the NEURAPRO clinical trial

Author

Susai, Subash Raj, Mongan, David, Healy, Colm, Cannon, Mary, Nelson, Barnaby, Markulev, Connie, Schäfer, Miriam R., Berger, Maximus, Mossaheb, Nilufar, Schlögelhofer, Monika, Smesny, Stefan, Hickie, Ian B., Berger, Gregor E., Chen, Eric Y.H., de Haan, Lieuwe, Nieman, Dorien H., Nordentoft, Merete, Riecher-Rössler, Anita, Verma, Swapna, Thompson, Andrew, Yung, Alison Ruth, McGorry, Patrick D., Föcking, Melanie, Cotter, David, and Amminger, G. Paul

Published
2022
Full Text
View/download PDF

3. Supplementation with the omega-3 long chain polyunsaturated fatty acids: Changes in the concentrations of omega-3 index, fatty acids and molecular phospholipids of people at ultra high risk of developing psychosis

Author

Alqarni, Ayedh, Mitchell, Todd W., McGorry, Patrick D., Nelson, Barnaby, Markulev, Connie, Yuen, Hok Pan, Schäfer, Miriam R., Berger, Maximus, Mossaheb, Nilufar, Schlögelhofer, Monika, Smesny, Stephan, Hickie, Ian B., Berger, Gregor E., Chen, Eric Y.H., de Haan, Lieuwe, Nieman, Dorien H., Nordentoft, Merete, Riecher-Rössler, Anita, Verma, Swapna, Thompson, Andrew, Yung, Alison Ruth, Meyer, Barbara J., and Amminger, G. Paul

Published
2020
Full Text
View/download PDF

4. Comparison of erythrocyte omega-3 index, fatty acids and molecular phospholipid species in people at ultra-high risk of developing psychosis and healthy people

Author

Alqarni, Ayedh, Mitchell, Todd W., McGorry, Patrick D., Nelson, Barnaby, Markulev, Connie, Yuen, Hok Pan, Schäfer, Miriam R., Berger, Maximus, Mossaheb, Nilufar, Schlögelhofer, Monika, Smesny, Stefan, Hickie, Ian B., Berger, Gregor E., Chen, Eric Y.H., de Haan, Lieuwe, Nieman, Dorien H., Nordentoft, Merete, Riecher-Rössler, Anita, Verma, Swapna, Thompson, Andrew, Yung, Alison Ruth, Amminger, G. Paul, and Meyer, Barbara J.

Published
2020
Full Text
View/download PDF

6. Cognitive functioning in ultra-high risk for psychosis individuals with and without depression: Secondary analysis of findings from the NEURAPRO randomized clinical trial

Author

Mallawaarachchi, Sumudu Rasangi, Amminger, G. Paul, Farhall, John, Bolt, Luke K., Nelson, Barnaby, Yuen, Hok Pan, McGorry, Patrick D., Markulev, Connie, Schäfer, Miriam R., Mossaheb, Nilufar, Schlögelhofer, Monika, Smesny, Stefan, Hickie, Ian B., Berger, Gregor Emanuel, Chen, Eric Y.H., de Haan, Lieuwe, Nieman, Dorien H., Nordentoft, Merete, Riecher-Rössler, Anita, Verma, Swapna, Thompson, Andrew, Yung, Alison Ruth, and Allott, Kelly A.

Published
2020
Full Text
View/download PDF

7. The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for Psychosis

Author

Amminger, G. Paul, Nelson, Barnaby, Markulev, Connie, Yuen, Hok Pan, Schäfer, Miriam R., Berger, Maximus, Mossaheb, Nilufar, Schlögelhofer, Monika, Smesny, Stephan, Hickie, Ian B., Berger, Gregor E., Chen, Eric Y.H., de Haan, Lieuwe, Nieman, Dorien H., Nordentoft, Merete, Riecher-Rössler, Anita, Verma, Swapna, Thompson, Andrew, Yung, Alison Ruth, and McGorry, Patrick D.

Published
2020
Full Text
View/download PDF

8. Trajectories of symptom severity and functioning over a three-year period in a psychosis high-risk sample: A secondary analysis of the Neurapro trial

Author

Hartmann, Jessica A., Schmidt, Stefanie J., McGorry, Patrick D., Berger, Maximus, Berger, Gregor E., Chen, Eric Y.H., de Haan, Lieuwe, Hickie, Ian B., Lavoie, Suzie, Markulev, Connie, Mossaheb, Nilufar, Nieman, Dorien H., Nordentoft, Merete, Polari, Andrea, Riecher-Rössler, Anita, Schäfer, Miriam R., Schlögelhofer, Monika, Smesny, Stefan, Thompson, Andrew, Verma, Swapna K., Yuen, Hok Pan, Yung, Alison R., Amminger, G. Paul, and Nelson, Barnaby

Published
2020
Full Text
View/download PDF

11. Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial

Author

Bolt, Luke K., Amminger, G. Paul, Farhall, John, McGorry, Patrick D., Nelson, Barnaby, Markulev, Connie, Yuen, Hok Pan, Schäfer, Miriam R., Mossaheb, Nilufar, Schlögelhofer, Monika, Smesny, Stefan, Hickie, Ian B., Berger, Gregor Emanuel, Chen, Eric Y.H., de Haan, Lieuwe, Nieman, Dorien H., Nordentoft, Merete, Riecher-Rössler, Anita, Verma, Swapna, Thompson, Andrew, Yung, Alison Ruth, and Allott, Kelly A.

Published
2019
Full Text
View/download PDF

15. Opening the Black Box of Cognitive-Behavioural Case Management in Clients with Ultra-High Risk for Psychosis

Author

Hartmann, Jessica A., McGorry, Patrick D., Schmidt, Stefanie J., Amminger, G. Paul, Yuen, Hok Pan, Markulev, Connie, Berger, Gregor E., Chen, Eric Y.H., de Haan, Lieuwe, Hickie, Ian B., Lavoie, Suzie, McHugh, Meredith J., Mossaheb, Nilufar, Nieman, Dorien H., Nordentoft, Merete, Riecher-Rössler, Anita, Schäfer, Miriam R., Schlögelhofer, Monika, Smesny, Stefan, Thompson, Andrew, Verma, Swapna Kamal, Yung, Alison R., and Nelson, Barnaby

Published
2017

27. NEURAPRO‐E study protocol: a multicentre randomized controlled trial of omega‐3 fatty acids and cognitive‐behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders

Author

Markulev, Connie, McGorry, Patrick D., Nelson, Barnaby, Yuen, Hok Pan, Schaefer, Miriam, Yung, Alison R., Thompson, Andrew, Berger, Gregor, Mossaheb, Nilufar, Schlögelhofer, Monika, Smesny, Stefan, de Haan, Lieuwe, Riecher‐Rössler, Anita, Nordentoft, Merete, Chen, Eric Yu Hai, Verma, Swapna, Hickie, Ian, and Amminger, G. Paul

Published
2017
Full Text
View/download PDF

32. Direct comparison of high-sensitivity-cardiac troponin I vs. T for the early diagnosis of acute myocardial infarction

Author

Rubini Gimenez, Maria, Twerenbold, Raphael, Reichlin, Tobias, Wildi, Karin, Haaf, Philip, Schaefer, Miriam, Zellweger, Christa, Moehring, Berit, Stallone, Fabio, Sou, Seoung Mann, Mueller, Mira, Denhaerynck, Kris, Mosimann, Tamina, Reiter, Miriam, Meller, Bernadette, Freese, Michael, Stelzig, Claudia, Klimmeck, Irina, Voegele, Janine, Hartmann, Beate, Rentsch, Katharina, Osswald, Stefan, and Mueller, Christian

Published
2014
Full Text
View/download PDF

34. NEURAPRO-E study protocol:a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders

Author

Markulev, Connie, McGorry, Patrick D, Nelson, Barnaby, Yuen, Hok Pan, Schaefer, Miriam, Yung, Alison R, Thompson, Andrew, Berger, Gregor, Mossaheb, Nilufar, Schlögelhofer, Monika, Smesny, Stefan, de Haan, Lieuwe, Riecher-Rössler, Anita, Nordentoft, Merete, Chen, Eric Yu Hai, Verma, Swapna, Hickie, Ian, Amminger, G Paul, Markulev, Connie, McGorry, Patrick D, Nelson, Barnaby, Yuen, Hok Pan, Schaefer, Miriam, Yung, Alison R, Thompson, Andrew, Berger, Gregor, Mossaheb, Nilufar, Schlögelhofer, Monika, Smesny, Stefan, de Haan, Lieuwe, Riecher-Rössler, Anita, Nordentoft, Merete, Chen, Eric Yu Hai, Verma, Swapna, Hickie, Ian, and Amminger, G Paul

Abstract

AIM: Recent research has indicated that preventative intervention is likely to benefit patients 'at-risk' for psychosis, both in terms of symptom reduction and delay or prevention of onset of threshold psychotic disorder. The strong preliminary results for the effectiveness of omega-3 polyunsaturated fatty acids (PUFAs), coupled with the falling transition rate in ultra high-risk (UHR) samples, mean that further study of such benign, potentially neuroprotective interventions is clinically and ethically required. Employing a multicentre approach, enabling a large sample size, this study will provide important information with regard to the use of omega-3 PUFAs in the UHR group.METHODS: This trial is a 6-month, double-blind, randomized placebo-controlled trial of 1.4 g day(-1) omega-3 PUFAs in UHR patients aged between 13 and 40 years. The primary hypothesis is that UHR patients receiving omega-3 PUFAs plus cognitive-behavioural case management (CBCM) will be less likely to transition to psychosis over a 6-month period compared to treatment with placebo plus CBCM. Secondary outcomes will examine symptomatic and functional changes, as well as examine if candidate risk factors predict response to omega-3 PUFA treatment in the UHR group.CONCLUSION: This is the protocol of the NeuraproE study. Utilizing a large sample, results from this study will be important in informing indicated prevention strategies for schizophrenia and other psychotic disorders, which may be the strongest avenue for reducing the burden, stigmatization, disability and economic consequences of these disorders.

Published
2017

36. Facial and vocal affect perception in people at ultra-high risk of psychosis, first-episode schizophrenia and healthy controls

Author

Amminger, G. Paul, Schaefer, Miriam R., Klier, Claudia M., Schloegelhofer, Monika, Mossaheb, Nilufar, Thompson, Andrew, Bechdolf, Andreas, Allott, Kelly, McGorry, Patrick D., Nelson, Barnaby, Amminger, G. Paul, Schaefer, Miriam R., Klier, Claudia M., Schloegelhofer, Monika, Mossaheb, Nilufar, Thompson, Andrew, Bechdolf, Andreas, Allott, Kelly, McGorry, Patrick D., and Nelson, Barnaby

Abstract

Aim: The study aims to investigate affect recognition in young people at different stages of psychotic illness. Methods: Seventy-nine ultra-high risk patients, 30 first-episode schizophrenia patients and 30 healthy control subjects completed a facial affect labelling test and an affective prosody recognition test. Psychiatric symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS). Results: We observed significant impairments in facial and vocal emotion recognition in both of the clinical groups compared with the control group. These group differences remained significant when age, sex and education were taken into account. Conclusions: The findings suggest that emotion recognition impairments may be independent of the stage of illness in schizophrenia. Deficits in emotion recognition may be present before the full expression of psychotic illness, and may contribute to the social cognition and social functioning deficits apparent in emerging psychotic disorders.

Published
2012

38. Effects of omega-3 PUFA on the vitamin E and glutathione antioxidant defense system in individuals at ultra-high risk of psychosis.

Author

Smesny, Stefan, Milleit, Berko, Schaefer, Miriam R., Hipler, Uta-Christina, Milleit, Christine, Wiegand, Cornelia, Hesse, Jana, Klier, Claudia M., Holub, Magdalena, Holzer, Ingrid, Berk, Michael, McGorry, Patrick D., Sauer, Heinrich, and Paul Amminger, G.

Abstract

Background Oxidative stress and impaired antioxidant defenses are reported in schizophrenia and are associated with disturbed neurodevelopment, brain structural alterations, glutamatergic imbalance, increased negative symptoms, and cognitive impairment. There is evidence that oxidative stress predates the onset of acute psychotic illness. Here, we investigate the effects of omega-3 PUFA on the vitamin E and glutathione antioxidant defense system (AODS). Method In 64 help-seeking UHR-individuals (13–25 years of age), vitamin E levels and glutathione were investigated before and after 12 weeks of treatment with either 1.2 g/d omega-3 (PUFA-E) or saturated fatty acids (SFA-E), with each condition also containing 30.4 mg/d alpha-tocopherol to ensure absorption without additional oxidative risk. Results In multivariate tests, the effects on the AODS (alpha-tocopherol, total glutathione) were not significantly different ( p =0.13, p =0.11, respectively) between treatment conditions. According to univariate findings, only PUFA-E caused a significant alpha-tocopherol increase, while PUFA-E and SFA-E caused a significant gamma- and delta-tocopherol decrease. Total glutathione (GSHt) was decreased by PUFA-E supplementation. Conclusion Effects of the PUFA-E condition on the vitamin E and glutathione AODS could be mechanisms underlying its clinical effectiveness. In terms of the vitamin E protection system, PUFA-E seems to directly support the antioxidative defense at membrane level. The effect of PUFA-E on GSHt is not yet fully understood, but could reflect antioxidative effects, resulting in decreased demand for glutathione. It is still necessary to further clarify which type of PUFA/antioxidant combination, and in which dose, is effective at each stage of psychotic illness. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

43. Polyunsaturated Fatty Acids in Emerging Psychosis

Author

Mossaheb, Nilufar, Schloegelhofer, Monika, R. Schaefer, Miriam, Fusar-Poli, Paolo, Smesny, Stefan, McGorry, Pat, Berger, Gregor, and Paul Amminger, G.

Abstract

The role of polyunsaturated fatty acids and their metabolites for the cause and treatment of psychotic disorders are widely discussed. The efficacy as an augmenting agent in chronic schizophrenia seems to be small or not present, however epidemiological data, as well as some recent controlled studies in emerging psychosis point towards possible preventive effects of long-chain polyunsaturated fatty acids in early and very early stages of psychotic disorders and some potential secondary or tertiary beneficial long-term effects in later, more chronic stages, in particular for metabolic or extra-pyramidal side effects. In this comprehensive review, we describe the physiology and metabolism of polyunsaturated fatty acids, phospholipases, epidemiological evidence and the effect of these fatty acids on the brain and neurodevelopment. Furthermore, we examine the available evidence in indicated prevention in emerging psychosis, monotherapy, add-on therapy and tolerability. The neuroprotective potential of n-3 LC-PUFAs for indicated prevention, i.e. delaying transition to psychosis in high-risk populations needs to be further explored.

Published
2012

46. NEURAPRO: A MULTI-CENTER RCT OF OMEGA-3 POLYUNSATURATED FATTY ACIDS VERSUS PLACEBO IN YOUNG PEOPLE AT ULTRA-HIGH RISK OF PSYCHOTIC DISORDERS: MEDIUM-TERM OUTCOME

Author

Nelson, Barnaby, Amminger, G. Paul, Markulev, Connie, Yuen, Hok Pan, Lavoie, Suzie, Schaefer, Miriam, Mossaheb, Nilu, Schloegelhofer, Monika, Smesny, Stefan, Hickie, Ian, Berger, Gregor, Chen, Eric, Haan, Lieuwe, Nieman, Dorien, Nordentoft, Merete, Riecher-Rossler, Anita, Verma, Swapna, Thompson, Andrew, Alison Yung, and Mcgorry, Patrick

48. NEURAPRO REVISITED: INCREASES IN LONG-CHAIN OMEGA-3 FATTY ACIDS IMPROVE FUNCTIONAL AND SYMPTOMATIC OUTCOMES IN ULTRAHIGH RISK PATIENTS

Author

Amminger, G. Paul, Nelson, Barnaby, Yuen, Hok Pan, Markulev, Connie, Schaefer, Miriam R., Schloegelhofer, Monika, Mossaheb, Nilufar, Smesny, Stephan, Hickie, Ian, Berger, Gregor, Chen, Eric, Haan, Lieuwe, Nieman, Dorien H., Nordentoft, Merete, Riecher-Roessler, Anita, Verma, Swapna, Berger, Maximus, andrew thompson, Yung, Alison, and Mcgorry, Patrick D.

49. THE NEURAPRO STUDY: ADHERENCE TO STUDY MEDICATION

Author

Schloegelhofer, Monika, Mcgorry, Patrick D., Nelson, Barnaby, Markulev, Connie, Yuen, Hok Pan, Schaefer, Miriam, Mossaheb, Nilufar, Smesny, Stefan, Hickie, Ian B., Berger, Gregor, Chen, Eric Y. H., Haan, Lieuwe, Nieman, Dorien H., Nordentoft, Merete, Riecher-Roessler, Anita, Verma, Swapna, Thompson, Andrew, Alison Yung, and Amminger, G. Paul

50. NEUROCOGNITION IN ULTRA-HIGHRISK INDIVIDUALS AND RELATIONSHIP TO TRANSITION TO PSYCHOSIS, DEPRESSIVE DISORDER, AND FUNCTIONING: FINDINGS FROM THE NEURAPRO TRIAL

Author

Allott, Kelly, Mcgorry, Patrick, Bolt, Luke, Nelson, Barnaby, Markulev, Connie, Yuen, Hok Pan, Schaefer, Miriam, Mossaheb, Nilufar, Schloegelhofer, Monika, Smesny, Stephan, Hickie, Ian, Berger, Gregor, Chen, Eric, Haan, Lieuwe, Nieman, Dorien, Nordentoft, Merete, Riecher-Rossler, Anita, Verma, Swapna, andrew thompson, Yung, Alison, and Amminger, G. Paul

Catalog

Books, media, physical & digital resources
See catalog results